IMDX Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
239.0K
+646.9%
32.0K
-97.2%
1.1M
+338.1%
260.0K
-49.8%
518.0K
Cost of Revenue
82.0K
+382.4%
17.0K
-97.4%
643.0K
+431.4%
121.0K
-32.8%
180.0K
Gross Profit
157.0K
+946.7%
15.0K
-97.0%
496.0K
+256.8%
139.0K
-58.9%
338.0K
Operating Expenses
11.6M
+11.7%
10.3M
-56.8%
23.9M
+113.9%
11.2M
+9.9%
10.2M
R&D
4.5M
-9.4%
5.0M
-15.0%
5.8M
+50.3%
3.9M
+18.6%
3.3M
SG&A
4.8M
-11.2%
5.4M
+16.8%
4.6M
+17.5%
3.9M
-4.3%
4.1M
Operating Income
-11402000
-10.4%
-10331000
+55.9%
-23435000
-112.1%
-11048000
-12.3%
-9842000
EBITDA
-10737000
-10.7%
-9700000
-17.3%
-8272000
+20.9%
-10464000
-12.7%
-9283000
Net Income
-11260000
-162.5%
-4290000
+81.3%
-22955000
-111.5%
-10854000
-11.4%
-9742000
EPS (Basic)
$-0.31
-158.3%
$-0.12
+83.1%
$-0.71
-108.8%
$-0.34
-13.3%
$-0.30
EPS (Diluted)
$-0.31
-158.3%
$-0.12
+83.1%
$-0.71
-108.8%
$-0.34
-13.3%
$-0.30
Shares (Diluted)
36.8M
+6.5%
34.5M
+7.4%
32.2M
+0.4%
32.0M
+0.0%
32.0M
Insight Molecular Diagnostics (IMDX) โ€” Financials